Literature DB >> 1561997

Interrelation of left ventricular ejection fraction, pulmonary congestion and outcome in acute myocardial infarction.

S Gottlieb1, A J Moss, M McDermott, S Eberly.   

Abstract

The interrelation of different grades of pulmonary congestion evaluated by chest roentgenogram in the coronary care unit, predischarge left ventricular (LV) ejection fraction (EF) and long-term prognosis was studied in 1,850 surviving patients of acute myocardial infarction (AMI). Pulmonary congestion was categorized as: none, mild or moderate, or severe; LVEF was classified as: greater than or equal to 40%, 25 to 39%, or less than 25%. The majority of patients (1,060; 57%) had an LVEF greater than or equal to 40% and no signs of pulmonary congestion. Severe pulmonary congestion was noted in 63 patients (3.4%), 17 with LVEF less than 25% and 16 with LVEF greater than or equal to 40%. One hundred twenty-five patients (6.8%) had an LVEF less than 25%, 49 of whom had no signs of pulmonary congestion. During a mean 2-year follow-up, cardiac mortality occurred in 212 patients (11.5%). The cardiac mortality rate was related to both predischarge LVEF impairment and severity of pulmonary congestion. Cardiac mortality hazard ratios (95% confidence intervals [CI]) for LVEF less than 25%, and 25 to 39% were 5.32 (CI 3.49, 8.13; p less than 0.0001) and 2.91 (CI 2.10, 4.02; p less than 0.0001), respectively, where a referent hazard ratio of 1 was assigned to patients with LVEF greater than or equal to 40% and to those with no pulmonary congestion. Development of pulmonary congestion during AMI significantly increased the cardiac mortality risk derived from LVEF, with a marked mortality effect in patients with severe pulmonary congestion; (hazard ratio 4.20; 95% CI 2.67, 6.62; p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1561997     DOI: 10.1016/0002-9149(92)90850-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.

Authors:  K S Spargias; A S Hall; D C Greenwood; S G Ball
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

Review 2.  Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.

Authors:  R Weir; J J V McMurray
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

Review 3.  What to expect from ACE inhibitors after myocardial infarction.

Authors:  S G Ball; A S Hall
Journal:  Br Heart J       Date:  1994-09

4.  Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.

Authors:  P K Schädlich; E Huppertz; J G Brecht
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

5.  Risk stratification after acute myocardial infarction by Doppler stroke distance measurement.

Authors:  R J Trent; J M Rawles
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

6.  ACE for whom? Implications for clinical practice of post-infarct trials.

Authors:  J T Walsh; D Gray; N A Keating; A J Cowley; J R Hampton
Journal:  Br Heart J       Date:  1995-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.